Tibet AIM Pharm. Inc. (SHE:002826)
China · Delayed Price · Currency is CNY 17.78
+0.53 (3.07%)
Aug 20, 2026, 3:04 PM CST
Tibet AIM Pharm. Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 3,380 | 3,442 | 1,901 | 2,263 | 1,943 | 2,094 | |
Market Cap Growth | -26.01% | 81.09% | -16.02% | 16.48% | -7.19% | 11.85% |
Enterprise Value | 2,746 | 2,891 | 1,527 | 1,981 | 1,724 | 1,954 |
Last Close Price | 17.78 | 18.20 | 10.22 | 11.67 | 9.92 | 10.56 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 34.79 | 37.18 | 41.39 | 147.10 | 44.03 | 49.29 |
PS Ratio | 5.04 | 5.41 | 2.92 | 3.39 | 2.27 | 2.89 |
PB Ratio | 4.03 | 4.22 | 2.55 | 3.02 | 2.59 | 2.91 |
P/TBV Ratio | 4.21 | 4.41 | 2.71 | 3.22 | 2.87 | 3.25 |
P/FCF Ratio | 20.68 | 29.87 | 19.14 | 13.83 | 29.78 | 24.83 |
P/OCF Ratio | 19.62 | 27.82 | 17.04 | 13.56 | 28.39 | 19.11 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 4.10 | 4.54 | 2.34 | 2.97 | 2.01 | 2.69 |
EV/EBITDA Ratio | 31.91 | 34.58 | 31.19 | 40.39 | 24.98 | 29.95 |
EV/EBIT Ratio | 40.54 | 44.74 | 56.01 | 79.53 | 37.22 | 46.99 |
EV/FCF Ratio | 16.81 | 25.09 | 15.37 | 12.10 | 26.42 | 23.17 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | - | 0.01 | 0.03 | 0.02 | 0.07 | - |
Debt / EBITDA Ratio | - | 0.13 | 0.47 | 0.22 | 0.73 | - |
Debt / FCF Ratio | - | 0.10 | 0.23 | 0.07 | 0.77 | - |
Net Debt / Equity Ratio | -0.76 | -0.64 | -0.54 | -0.50 | -0.36 | -0.25 |
Net Debt / EBITDA Ratio | -7.36 | -6.29 | -8.26 | -7.64 | -3.93 | -2.80 |
Net Debt / FCF Ratio | -3.88 | -4.57 | -4.07 | -2.29 | -4.16 | -2.17 |
Asset Turnover | 0.64 | 0.66 | 0.70 | 0.69 | 0.93 | 0.84 |
Inventory Turnover | 2.56 | 2.26 | 4.11 | 6.23 | 12.15 | 17.12 |
Quick Ratio | 2.55 | 2.90 | 2.74 | 2.51 | 2.00 | 3.22 |
Current Ratio | 2.78 | 3.22 | 3.01 | 2.86 | 2.19 | 3.65 |
Return on Equity (ROE) | 11.69% | 11.93% | 6.35% | 2.10% | 6.27% | 6.18% |
Return on Assets (ROA) | 4.05% | 4.15% | 1.84% | 1.60% | 3.14% | 3.00% |
Return on Invested Capital (ROIC) | 21.88% | 16.79% | 5.99% | 3.89% | 7.41% | 6.82% |
Return on Capital Employed (ROCE) | 8.00% | 7.90% | 3.60% | 3.30% | 6.10% | 5.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 2.76% | 2.69% | 2.42% | 0.68% | 2.27% | 2.03% |
FCF Yield | 4.83% | 3.35% | 5.23% | 7.23% | 3.36% | 4.03% |
Dividend Yield | 0.83% | 0.82% | 0.98% | 0.26% | 1.01% | 0.95% |
Payout Ratio | 25.32% | 25.75% | 13.14% | 131.81% | 44.78% | 35.95% |
Buyback Yield / Dilution | 0.74% | -0.79% | 4.48% | -0.23% | 0.61% | -3.37% |
Total Shareholder Return | 1.57% | 0.04% | 5.46% | 0.03% | 1.62% | -2.42% |